In view of the advancement in the understanding about the most diverse types of cancer and
consequently a relentless search for a cure and increased survival rates of cancer patients …

In recent years, oncolytic virotherapy has emerged as a promising anticancer therapy.
Oncolytic viruses destroy cancer cells, without damaging normal tissues, through virus self …

Leveraging the immune system to thwart cancer is not a novel strategy and has been
explored via cancer vaccines and use of immunomodulators like interferons. However, it …

Abstract Background Enadenotucirev (formerly ColoAd1) is a tumor-selective chimeric
adenovirus with demonstrated preclinical activity. This phase 1 Mechanism of Action study …

Oncolytic reovirus can be delivered both systemically and intratumorally, in both preclinical
models and in early phase clinical trials. Reovirus has direct oncolytic activity against a …

Oncolytic viruses (OVs) are viral strains that can infect and kill malignant cells while spare
their normal counterparts. OVs can access cells through binding to receptors on their surface …

Oncolytic viruses have had a tumultuous course, from the initial anecdotal reports of patients
having antineoplastic effects after natural viral infections a century ago to the development of …

Simple Summary Within this review article the authors provide an unbiased review of the
oncolytic virus, reovirus, clinically formulated as pelareorep. In particular, the authors …

Oncolytic viruses, which preferentially lyse cancer cells and stimulate an antitumor immune
response, represent a promising approach to the treatment of cancer. However, how they …

Cancer immunotherapies, widely heralded as transformational for many adult cancer
patients, are becoming viable options for selected subsets of pediatric cancer patients. Many …